Eli Lilly concludes POINT Biopharma acquisition for $1.4bn

Eli Lilly concludes POINT Biopharma acquisition for $1.4bn

Submitted by admin on December 31, 2023 - 11:40am
Source: 
Pharmaceutical Business Review
News Tags: 
Eli Lilly
Point Biopharma
M&A
radiopharmaceuticals
Headline: 
Eli Lilly concludes POINT Biopharma acquisition for $1.4bn
snippet: 


Eli Lilly and Company has concluded the acquisition of all outstanding shares of radiopharmaceutical company POINT Biopharma in a deal valued at nearly $1.4bn.

Do Not Allow Advertisers to Use My Personal information